As clinically shown, the use of repurposed targeted therapies, e.g., mTOR inhibitors, may contribute to long-term tumor control or cCR in r/r tumor disease, e.g., Hodgkin’s lymphoma or uveal melanoma [22,37]. The gene discussed is MTOR; the disease is neoplasm.